We also used a tumor slice platform to demonstrate that a combination of FGFR inhibitor plus ICB mediated by PD‐1 and PD‐L1 effectively inhibits FGFR2‐induced tumorigenesis. This evidence concerns the gene FGFR2 and neoplasm.